VolitionRx Limited APIC, Share-based Payment Arrangement, Increase for Cost Recognition
VolitionRx Limited (VNRX) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $238.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-13
- VolitionRx Limited apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $238.00K, a 70.69% decline year-over-year.
- VolitionRx Limited apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $224.98K, a 35.31% decline year-over-year.
- VolitionRx Limited apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $609.17K, a 88.28% increase year-over-year.
- VolitionRx Limited apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $812.04K, a 290.32% increase year-over-year.
- VolitionRx Limited apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $1.64M, a 28.98% increase from fiscal 2024.
- VolitionRx Limited apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $1.27M.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $238.00K 10-Q · filed 2026-08-13 | $462.98K derived: sum of 2 quarters · filed 2026-08-13 | ||
| 2026-03-31 | $224.98K 10-Q · filed 2026-08-13 | |||
| 2025-12-31 | $1.64M 10-K · filed 2026-03-31 | |||
| 2025-09-30 | $609.17K 10-Q · filed 2025-11-13 | $1.42M derived: sum of 2 quarters · filed 2026-08-13 | $1.77M derived: sum of 3 quarters · filed 2026-08-13 | |
| 2025-06-30 | $812.04K 10-Q · filed 2026-08-13 | $1.16M derived: sum of 2 quarters · filed 2026-08-13 | ||
| 2025-03-31 | $347.80K 10-Q · filed 2026-08-13 | |||
| 2024-12-31 | $1.27M 10-K · filed 2026-03-31 | |||
| 2024-09-30 | $323.54K 10-Q · filed 2025-11-13 | $531.59K derived: sum of 2 quarters · filed 2025-11-13 | $942.80K derived: sum of 3 quarters · filed 2025-11-13 | |
| 2024-06-30 | $208.05K 10-Q · filed 2025-11-13 | $619.27K derived: sum of 2 quarters · filed 2025-11-13 | ||
| 2024-03-31 | $411.22K 10-Q · filed 2025-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |